SA
GMAB logo
Genmab A/S(GMAB)
Closing price · checked 8:25 PM ETAbout this dataData status
$50.60▼-0.75 (-1.46%)
Extended:$50.02-0.58 (-1.15%)· 8:25 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Genmab A/S (GMAB)

R&D to Revenue

41.91%

Fiscal year · Period ending:

GMAB logo

GMAB R&D to Revenue

Latest reported41.91%
GMAB FY R&D/Revenue (0.00% → 41.91%)
Powered by
High-resolution chart · PNG

What is r&d to revenue?

R&D spending as percentage of revenue.

GMAB r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it, in percentage points.

Genmab A/S R&D to Revenue — Annual fiscal periods
Period endingR&D to RevenueChange
41.9086%−3.38 pts
45.2848%−1.03 pts
46.3154%+7.97 pts
38.3454%−10.95 pts
49.2926%+18.27 pts
31.0256%−13.44 pts
44.4652%−2.84 pts
47.3089%+10.35 pts
36.9605%+0.57 pts
36.3894%−6.65 pts
43.0396%−16.43 pts
59.4647%−20.04 pts
79.5057%−31.24 pts
110.7433%−41.00 pts
151.7391%+54.53 pts
97.2114%−62.39 pts
159.5972%−20.61 pts
180.203%+63.40 pts
116.8007%−148.76 pts
265.5559%−43.16 pts
308.7183%−8,794.67 pts
9,103.3894%+8,597.02 pts
506.3709%+506.37 pts
0%—

Frequently asked questions: GMAB r&d to revenue

What is Genmab A/S (GMAB)'s current r&d to revenue?

Genmab A/S (GMAB)'s latest reported r&d to revenue (Fiscal year) is 41.91% as of Dec 31, 2025. R&D spending as percentage of revenue.

How much historical r&d to revenue data is available for GMAB?

Stock Alarm Pro provides 24 dated annual fiscal periods observations for Genmab A/S (GMAB)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare GMAB's r&d to revenue to peers or set an alert?

You can open GMAB's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on GMAB delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.